Jesster, I appreciate the response.
Even though the NIH trial using DCVax is 7 or 8 years, let's hope the study data can be useful to NWBO post-DCVax-L approval. We both agree they had amazing results, with 43 patients, for rare and high-risk pediatric cancers. I hope it will come to be support for DCVax in regulatory, commercial, and trial considerations in the future for pediatric expansion, based on these amazing immune response and survival outcomes.
On the idea of not believing in everything that has a possibility. I agree. There are degrees of that. I appreciate people and their constructive ideas, those who provide their reasoning, and less when there is less. We all are coping with an extended wait. Some research the science, others provide humor (not so much of that recently), and others brood over stock price.
I will just say, Linda Powers is not sitting on her hands. There is so much going on in the background, that there is much legit research for us investors to do in the form of due diligence. And Andrew is making a great contribution in that area. And we all contribute in our own way. Best.
Sharing thoughts and opinions. To participate in group due diligence. Motto: Do not be a gullible FUDdable investor.
Market Data 
Markets 
